Brinker Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brinker Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$218K	Buy	+3,929	New	+$168K	0.01%	889
2017 Q2	–	Sell	-15,379	Closed	-$227K	–	937
2017 Q1	$227K	Buy	15,379 +2,399	+18%	+$38.9K	0.01%	855
2016 Q4	$210K	Buy	+12,980	New	+$235K	0.01%	650

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Brinker Capital's HZNP Position: Q2 2020 in Review

Brinker Capital opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2020: 3,929 shares worth $218K. The stake represents 0.01% of the portfolio and ranks #889 among its holdings. This is a return to the name: Brinker Capital previously reported a position in HZNP as recently as Q1 2017.

Brinker Capital first reported a position in HZNP in Q4 2016 and has held it in 3 quarters since. The position peaked at $227K in Q1 2017. 354 funds tracked by Wall St. Rank hold HZNP as of Q2 2020.

Brinker Capital held 3,929 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $218K as of Q2 2020.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Brinker Capital position in Q2 2020.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of Brinker Capital's portfolio in Q2 2020, its #889 holding.
Brinker Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and has held it in 3 quarters since.
Brinker Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $227K in Q1 2017.
354 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.